27 Feb 2014 07:00
27 February 2014
Silence Therapeutics is pleased to give the following year end trading update.
Significant progress is being made in both the pre clinic and the clinical areas. Our programs are on track: patient enrolment for our Phase IIa trial in pancreatic cancer is progressing, we expect to begin our head and neck oncology Phase Ib trial in H2 2014, and are on track to file an IND for our lung indication, Atu111, in H2 2014/H1 2015.
Silence has one of the broadest delivery capabilities in the RNA industry, targeting the vasculature, the lung and the liver.
As well as a leading global position in using these delivery capabilities to deliver siRNA (short interfering RNA) to target cells, we are actively exploring other attractive payloads such as MicroRNA and mRNA (messenger RNA), where we have promising pre clinical data.
The net cash position as at 26 February 2014 was £19.3m.
For further information contact:
Silence Therapeutics plc | +44 (0)203 700 9711 |
Ali Mortazavi, Chief Executive | a.mortazavi@silence-therapeutics.com |
Timothy Freeborn, Finance Director | t.freeborn@silence-therapeutics.com |
Annie Cheng, Chief Operating Officer | a.cheng@silence-therapeutics.com |
Canaccord Genuity Limited | +44 (0)207 523 8350 |
Lucy Tilley | |
Dr Julian Feneley | |
Henry Fitzgerald-O'Connor | |